Stifel analyst Rick Wise reiterated a Buy rating and $110.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst commented, "The high-level optics from Edwards 1Q26 earnings report were very encouraging. Both revenues and EPS beat us and Consensus projections, TAVR grew double-digits for the third consecutive quarter, the company's minimally invasive mitral-valve-repair product, PASCAL, clearly gained share, and 2026 financial guidance was raised. Looking ahead, we viewed the company's overall 1Q26 messaging as "prudently optimistic". On one hand, management noted that they face tougher 2H26 comps, underpinning the expected 2H26 lower revenue growth rates. At the same time, the company expressed confidence in the extensive data supporting TAVR, as well as other factors like the upcoming CMS national-coverage-determination update, as potential TAVR growth tailwinds. Beyond TAVR, the company's mitral and tricuspid valve disease innovation pipeline remains full of next-gen devices, new indications, and incremental technology launches/approvals. Net-net, with TAVR growth stable to improving and the TMTT division gaining share, Edwards appears very well-set-up to deliver durable, double-digit revenue growth."

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $79.72 yesterday.